An analysis of pancreatic cancer data in younger adults found that while there is an increasing incidence of pancreatic cancer in young adults, the mortality rate remains stable.
Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).